Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Replimune Group, Inc. (REPL : NSDQ)
 
 • Company Description   
Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States.

Number of Employees: 152

 
 • Price / Volume Information   
Yesterday's Closing Price: $14.53 Daily Weekly Monthly
20 Day Moving Average: 417,693 shares
Shares Outstanding: 47.21 (millions)
Market Capitalization: $685.96 (millions)
Beta: 2.29
52 Week High: $40.22
52 Week Low: $13.05
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -17.21% -9.28%
12 Week -9.75% -2.08%
Year To Date -46.38% -36.24%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
500 Unicorn Park
-
WOBURN,MA 01801
USA
ph: 781-222-9600
fax: -
ir@replimune.com http://www.replimune.com
 
 • General Corporate Information   
Officers
Philip Astley-Sparke - Chief Executive Officer and Director
Robert Coffin - President and Chief Research & Development Officer
Jean Franchi - Chief Financial Officer and Treasurer
Kapil Dhingra - Director
Hyam Levitsky - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 76029N106
SIC: 2836
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 05/19/22
Share - Related Items
Shares Outstanding: 47.21
Most Recent Split Date: (:1)
Beta: 2.29
Market Capitalization: $685.96 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.70 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/19/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.56
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -29.55%
vs. Previous Quarter: -1.79%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -23.03
09/30/21 - -20.49
ROA
03/31/22 - -
12/31/21 - -20.99
09/30/21 - -18.77
Current Ratio
03/31/22 - -
12/31/21 - 23.39
09/30/21 - 26.71
Quick Ratio
03/31/22 - -
12/31/21 - 23.39
09/30/21 - 26.71
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - 9.33
09/30/21 - 9.78
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.06
09/30/21 - 0.05
Debt-to-Capital
03/31/22 - -
12/31/21 - 5.30
09/30/21 - 5.10
 

Powered by Zacks Investment Research ©